Journey Medical Corporation (DERM)
| Market Cap | 147.31M +2.2% |
| Revenue (ttm) | 61.86M +10.2% |
| Net Income | -11.43M |
| EPS | -0.47 |
| Shares Out | 27.33M |
| PE Ratio | n/a |
| Forward PE | 74.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 403,865 |
| Open | 5.29 |
| Previous Close | 5.17 |
| Day's Range | 5.14 - 5.60 |
| 52-Week Range | 4.31 - 9.56 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 12.67 (+135.07%) |
| Earnings Date | May 13, 2026 |
About DERM
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to se... [Read more]
Financial Performance
In 2025, Journey Medical's revenue was $61.86 million, an increase of 10.20% compared to the previous year's $56.13 million. Losses were -$11.43 million, -22.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price target is $12.67, which is an increase of 135.07% from the latest price.
News
Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Journey Medical Corporation (NASDAQ: DERM). The investigation focuses on ...
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Appro...
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on sk...
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call toda...
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provid...
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory ...
Journey Medical Corporation to Participate in October 2025 Investor Conferences
SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on sel...
Journey Medical Corporation to Participate in September 2025 Investor Conferences
SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on se...
Journey Medical Corporation to Present at the Emerging Growth Conference
SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily f...
CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Wednesday.
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June ...
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that pri...
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide ...
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOT...
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that pri...
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treati...
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz.
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions ...
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...
Top 3 Health Care Stocks That May Crash In Q2
As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses ...
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended D...
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Med...
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...